Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions
KRYS Stock Forecast
Krystal Biotech stock forecast is as follows: an average price target of $210.33 (represents a 27.60% upside from KRYS’s last price of $164.83) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
KRYS Price Target
The average price target for Krystal Biotech (KRYS) is $210.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $220.00 to $205.00. This represents a potential 27.60% upside from KRYS's last price of $164.83.
KRYS Analyst Ratings
According to 8 Wall Street analysts, Krystal Biotech's rating consensus is 'Buy'. The analyst rating breakdown for KRYS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Krystal Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | 18.92% | 33.47% |
| Sep 02, 2024 | Alec Stranahan | Bank of America Securities | $205.00 | $195.12 | 5.06% | 24.37% |
| Aug 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $206.00 | $182.17 | 13.08% | 24.98% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $204.00 | $169.75 | 20.18% | 23.76% |
| Nov 07, 2022 | Geulah Livshits | Chardan Capital | $133.00 | $78.05 | 70.40% | -19.31% |
| Aug 08, 2022 | Geulah Livshits | Chardan Capital | $130.00 | $82.40 | 57.77% | -21.13% |
The latest Krystal Biotech stock forecast, released on Sep 11, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $220.00, which represents a 18.92% increase from the stock price at the time of the forecast ($185.00), and a 33.47% increase from KRYS last price ($164.83).
Krystal Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $208.75 |
| Last Closing Price | $164.83 | $164.83 | $164.83 |
| Upside/Downside | -100.00% | -100.00% | 26.65% |
In the current month, the average price target of Krystal Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Krystal Biotech's last price of $164.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Citigroup | Neutral | Neutral | Hold |
| Sep 11, 2024 | Wedbush | Underperform | Underperform | Hold |
| Sep 11, 2024 | National Securities Corporation | Buy | Buy | Hold |
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 05, 2024 | Citigroup | Buy | Neutral | Downgrade |
| Feb 27, 2024 | Guggenheim | Buy | Buy | Hold |
| Feb 27, 2024 | Citigroup | Buy | Buy | Hold |
| May 22, 2023 | Barclays | Buy | Buy | Hold |
| Feb 28, 2023 | Goldman Sachs | Buy | Upgrade |
Krystal Biotech's last stock rating was published by Citigroup on Nov 04, 2024. The company gave KRYS a "Neutral" rating, the same as its previous rate.
Krystal Biotech Financial Forecast
Krystal Biotech Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.56M | - | - | - |
| Avg Forecast | $226.17M | $195.91M | $165.57M | $145.26M | $142.10M | $143.72M | $138.26M | $102.78M | $124.28M | $114.83M | $109.18M | $92.13M | $91.55M | $82.94M | $65.27M | $47.37M | $28.55M | $6.29M | $142.86K | $663.41K | $290.29K |
| High Forecast | $234.95M | $203.51M | $172.00M | $150.90M | $147.62M | $149.30M | $143.62M | $106.77M | $129.10M | $119.29M | $113.42M | $95.70M | $93.59M | $83.56M | $65.27M | $47.37M | $44.93M | $6.29M | $148.40K | $796.10K | $348.34K |
| Low Forecast | $213.69M | $185.10M | $156.44M | $137.25M | $134.26M | $135.79M | $130.63M | $97.11M | $117.42M | $108.49M | $103.16M | $87.04M | $87.73M | $82.33M | $65.27M | $47.37M | $12.82M | $6.29M | $134.97K | $530.73K | $232.23K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | - | - | - |
Krystal Biotech's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.55M, with a low forecast of $12.82M, and a high forecast of $44.93M. KRYS's average Quarter revenue forecast represents a 233.70% increase compared to the company's last Quarter revenue of $8.56M (Sep 23).
Krystal Biotech EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.99M | $-23.12M | $-3.98M | $-2.13M |
| Avg Forecast | $196.91M | $170.56M | $144.15M | $126.47M | $123.72M | $125.13M | $120.37M | $89.48M | $108.20M | $99.97M | $95.06M | $80.21M | $79.71M | $72.21M | $56.83M | $41.24M | $24.86M | $5.48M | $124.38K | $-5.11M | $-3.18M |
| High Forecast | $204.55M | $177.18M | $149.75M | $131.38M | $128.52M | $129.99M | $125.04M | $92.95M | $112.40M | $103.85M | $98.75M | $83.32M | $81.48M | $72.75M | $56.83M | $41.24M | $39.12M | $5.48M | $129.20K | $-4.09M | $-2.54M |
| Low Forecast | $186.05M | $161.15M | $136.20M | $119.49M | $116.89M | $118.23M | $113.73M | $84.54M | $102.23M | $94.46M | $89.81M | $75.78M | $76.38M | $71.68M | $56.83M | $41.24M | $11.16M | $5.48M | $117.51K | $-6.14M | $-3.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.74% | -185.87% | 0.78% | 0.67% |
undefined analysts predict KRYS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Krystal Biotech's previous annual EBITDA (undefined) of $NaN.
Krystal Biotech Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.75M | $-41.77M | $-4.11M | $-2.15M |
| Avg Forecast | $83.28M | $67.03M | $50.60M | $50.04M | $39.49M | $41.99M | $40.19M | $25.25M | $41.13M | $37.99M | $36.00M | $31.93M | $35.34M | $29.71M | $21.91M | $7.96M | $-9.22M | $-35.92M | $-43.01M | $-4.61M | $-3.02M |
| High Forecast | $87.48M | $70.41M | $53.15M | $52.57M | $41.48M | $44.10M | $42.22M | $26.52M | $43.20M | $39.91M | $37.81M | $37.42M | $51.18M | $30.16M | $21.92M | $7.96M | $-354.56K | $-33.34M | $-39.93M | $-3.69M | $-2.42M |
| Low Forecast | $77.31M | $62.22M | $46.97M | $46.45M | $36.66M | $38.97M | $37.31M | $23.44M | $38.18M | $35.27M | $33.42M | $26.43M | $27.14M | $29.25M | $21.91M | $7.96M | $-16.84M | $-37.73M | $-45.18M | $-5.53M | $-3.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.25% | 0.97% | 0.89% | 0.71% |
Krystal Biotech's average Quarter net income forecast for Dec 23 is $-9.22M, with a range of $-16.84M to $-354.56K. KRYS's average Quarter net income forecast represents a -111.42% decrease compared to the company's last Quarter net income of $80.75M (Sep 23).
Krystal Biotech SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $23.70M | $24.04M | $1.53M | $757.00K |
| Avg Forecast | $268.73M | $232.77M | $196.73M | $172.60M | $168.84M | $170.77M | $164.28M | $122.12M | $147.66M | $136.44M | $129.73M | $109.46M | $108.78M | $98.55M | $77.56M | $56.28M | $33.92M | $7.48M | $169.74K | $775.15K | $339.18K |
| High Forecast | $279.16M | $241.80M | $204.36M | $179.30M | $175.39M | $177.40M | $170.65M | $126.86M | $153.39M | $141.73M | $134.76M | $113.71M | $111.20M | $99.28M | $77.56M | $56.28M | $53.38M | $7.48M | $176.33K | $930.18K | $407.01K |
| Low Forecast | $253.91M | $219.93M | $185.87M | $163.08M | $159.53M | $161.35M | $155.21M | $115.38M | $139.52M | $128.91M | $122.57M | $103.42M | $104.24M | $97.83M | $77.56M | $56.28M | $15.23M | $7.48M | $160.37K | $620.12K | $271.34K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.17% | 141.60% | 1.97% | 2.23% |
Krystal Biotech's average Quarter SG&A projection for Dec 23 is $33.92M, based on 6 Wall Street analysts, with a range of $15.23M to $53.38M. The forecast indicates a 43.16% rise compared to KRYS last annual SG&A of $23.70M (Sep 23).
Krystal Biotech EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.88 | $-1.62 | $-0.29 | $-0.21 |
| Avg Forecast | $2.79 | $2.24 | $1.69 | $1.67 | $1.32 | $1.40 | $1.34 | $0.84 | $1.38 | $1.27 | $1.20 | $1.07 | $1.18 | $0.99 | $0.73 | $0.27 | $-0.31 | $-1.20 | $-1.44 | $-0.33 | $-0.67 |
| High Forecast | $2.93 | $2.35 | $1.78 | $1.76 | $1.39 | $1.47 | $1.41 | $0.89 | $1.44 | $1.33 | $1.26 | $1.25 | $1.71 | $1.01 | $0.73 | $0.27 | $-0.01 | $-1.12 | $-1.34 | $-0.33 | $-0.54 |
| Low Forecast | $2.59 | $2.08 | $1.57 | $1.55 | $1.23 | $1.30 | $1.25 | $0.78 | $1.28 | $1.18 | $1.12 | $0.88 | $0.91 | $0.98 | $0.73 | $0.27 | $-0.56 | $-1.26 | $-1.51 | $-0.33 | $-0.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.40% | 1.13% | 0.88% | 0.31% |
According to 6 Wall Street analysts, Krystal Biotech's projected average Quarter EPS for Dec 23 is $-0.31, with a low estimate of $-0.56 and a high estimate of $-0.01. This represents a -110.70% decrease compared to KRYS previous annual EPS of $2.88 (Sep 23).